BR112015024583A2 - vacina conjugada de peptídeo antigênico wt1 - Google Patents
vacina conjugada de peptídeo antigênico wt1Info
- Publication number
- BR112015024583A2 BR112015024583A2 BR112015024583A BR112015024583A BR112015024583A2 BR 112015024583 A2 BR112015024583 A2 BR 112015024583A2 BR 112015024583 A BR112015024583 A BR 112015024583A BR 112015024583 A BR112015024583 A BR 112015024583A BR 112015024583 A2 BR112015024583 A2 BR 112015024583A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- class
- restricted
- cancer
- antigenic peptide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 108010060123 Conjugate Vaccines Proteins 0.000 title abstract 2
- 229940031670 conjugate vaccine Drugs 0.000 title abstract 2
- 239000000863 peptide conjugate Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 230000000890 antigenic effect Effects 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 5
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo patente de invenção: "vacina conjugada de peptídeo antigênico wt1". a presente invenção refere-se a um composto representado pela fórmula (1): em que xa e ya são, cada um, uma ligação simples e assim por diante, o peptídeo antigênico de câncer a é um peptídeo de wt1 restrito a moléculas do mhc de classe i que consiste em 7 - 30 resíduos de aminoácidos, r1 é um átomo de hidrogênio, um grupo representado pela fórmula (2): em que xb e yb são, cada um, uma ligação simples e assim por diante, o peptídeo antigênico de câncer b tem uma sequência diferente daquela do peptídeo antigênico de câncer a e é um peptídeo de wt1 restrito a moléculas do mhc de classe i que consiste em 7 - 30 resíduos de aminoácidos ou o peptídeo antigênico de câncer c e o peptídeo antigênico de câncer c tem uma sequência diferente daquela do peptídeo antigênico de câncer a e é um peptídeo de wt1 restrito a moléculas do mhc de classe i ou um peptídeo de wt1 restrito a moléculas do mhc de classe i, que consiste em 7 - 30 resíduos de aminoácidos contendo um resíduo de cisteína, ou um sal do mesmo e assim por diante. 1/1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013072173 | 2013-03-29 | ||
JP2013-072173 | 2013-03-29 | ||
JP2013-158383 | 2013-07-31 | ||
JP2013158383 | 2013-07-31 | ||
PCT/JP2014/059336 WO2014157692A1 (ja) | 2013-03-29 | 2014-03-28 | Wt1抗原ペプチドコンジュゲートワクチン |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015024583A2 true BR112015024583A2 (pt) | 2017-10-31 |
BR112015024583A8 BR112015024583A8 (pt) | 2023-05-09 |
BR112015024583B1 BR112015024583B1 (pt) | 2023-09-05 |
Family
ID=
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502180A1 (en) | Wt1-antigen peptide conjugate vaccine | |
CY1124112T1 (el) | Νευροδραστικα στεροειδη, συνθεσεις, και χρησεις αυτων | |
CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
BR112016002083A2 (pt) | composto tetrazolinona e uso para o mesmo | |
BR112018015570A2 (pt) | análogos de canabidiol biologicamente ativos | |
BR112018067792A2 (pt) | preparação contendo o anticorpo | |
BR122021005860A8 (pt) | Derivados de aminoácidos e composição que os compreende | |
EA201690623A1 (ru) | Простациклиновые соединения, композиции и способы их использования | |
MX2017005199A (es) | Conjugados y reactivos de conjugacion. | |
BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
BR112015010649A2 (pt) | moduladores de gpr40 à base de pirrolidina | |
BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
MX370354B (es) | Ligando de receptor de neurotensina. | |
BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
BR112015023829A2 (pt) | composto de amidina e seu uso | |
BR112015029504A2 (pt) | inibidores quinase | |
PE20141206A1 (es) | Procesos para la elaboracion de depsipeptidos macrociclicos y nuevos intermediarios | |
AR100913A1 (es) | Síntesis de complejo de zinc-lisina a partir de cloruro de zinc | |
BR112016027760A8 (pt) | método de síntese de ph baixo de complexo de zinco-lisina | |
BR112019006301A2 (pt) | peptídeo cíclico, suporte de cromatografia de afinidade, anticorpo marcado, conjugado anticorpo - fármaco, e preparação farmacêutica | |
BR112012020703A2 (pt) | composição para o controle de pragas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP) |
|
B25G | Requested change of headquarter approved |
Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP) |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2014, OBSERVADAS AS CONDICOES LEGAIS |